

EXPANDED ACCESS PROGRAM TO TREAT PATIENTS WITH PREVIOUSLY TREATED METASTATIC PANCREATIC ADENOCARCINOMA WITH DARAXONRASIB

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 18 years of age or older able to take oral medication - diagnosed with metastatic pancreatic cancer that has grown or spread after previous treatment - received at least one prior treatment for metastatic pancreatic cancer - see link to [ClinicalTrials.gov](https://clinicaltrials.gov) for complete Inclusion Criteria

Exclusion Criteria:

- pancreatic cancer that has spread to the brain or central nervous system - currently receiving another cancer treatment - significant heart disease or an active, uncontrolled infection - major surgery within the past 28 days - see link to [ClinicalTrials.gov](https://clinicaltrials.gov) for complete Exclusion Criteria

Conditions & Interventions

Conditions:

Cancer

Keywords:

Clinics and Surgery Center, CSC, Clinics and Surgery Center (CSC), pancreatic adenocarcinoma, pancreatic cancer

More Information

Description: The purpose of this study is to evaluate the investigational medication daraxonrasib in people with metastatic pancreatic cancer whose disease has progressed after previous treatment, who have no satisfactory treatment options, and who are unable to participate in a daraxonrasib clinical trial.

Study Contact: Simone Veum - veum0015@umn.edu

Principal Investigator: Alex Tsai

IRB Number: STUDY00028794

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.